Loading
A phase 3 trial testing FDA018-ADC in triple-negative breast cancer, active and no longer recruiting.
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer is a phase 3 interventional study registered as NCT06519370, led by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Phase 3, Open-label, Randomised Study of FDA018-ADC Versus Investigator's Choice of Chemotherapy in Patients Who Recurred During or After Taxane Therapy in Locally Advanced or Metastatic Triple-negative Breast Cancer. Planned enrolment is 350 participants (estimated). The study started in 2024-08-09 and primary completion is expected in 2026-08-18. No results have been posted on ClinicalTrials.gov.
Shares Fudan University Shanghai Cancer Center, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Fudan University Shanghai Cancer Center, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).